Research Article

Antidiabetic Activity of *Picris japonica* Thunb Aqueous Extract in Diabetic KK-AY Mice

Yanmei Jia and Lirong Chen

*Laboratory Medicine Department, Fenyang College of Shanxi Medical University, Fenyang, 032200, China*

Correspondence should be addressed to Yanmei Jia; fyjym2018@163.com

Received 7 May 2018; Revised 8 July 2018; Accepted 1 November 2018; Published 12 November 2018

Academic Editor: Darren R. Williams

Copyright © 2018 Yanmei Jia and Lirong Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objective.** To evaluate the hypoglycemic effect of *Picris japonica* Thunb (Asteraceae) on KK-Ay mice.

**Methods.** The hypoglycemic effect of *Picris japonica* aqueous extract (PJE) in a spontaneous type 2 diabetic model (KK-Ay mice) was studied in the present research. PJE was administrated at doses of 700 mg/kg and 350 mg/kg (calculated as crude herb) for 14 days and blood glucose, oral glucosetolerance test, plasma insulin level, and blood lipid were evaluated. Meanwhile, Rosiglitazone was used for the positive control.

**Results.** It was found the PJE treatment significantly reduced blood glucose level and improved oral glucose tolerance ability ($p < 0.01$ or $p < 0.05$) in a dose-dependent manner compared to the control diabetic mice. The blood insulin levels were significantly reduced in PJE-treated mice (700 mg/kg) and Rosiglitazone compared with the diabetic control ($p < 0.01$). Compared with the control diabetic group, the serum total cholesterol, triglyceride, and low density lipoprotein cholesterol were reduced by PJE (700 mg/kg) and Rosiglitazone ($p < 0.05$), and the serum high density lipoprotein cholesterol was significantly increased only by Rosiglitazone ($p < 0.01$).

**Conclusions.** The findings demonstrate that *Picris japonica* has remarkable antidiabetic effect in diabetic KK-Ay mice, which suggests that *Picris japonica* may be beneficial to the treatment of type 2 diabetes mellitus.

1. Introduction

Diabetes mellitus is a chronic metabolic disorder, which can be classified into two types: type 1 diabetes (insulin-dependent diabetes mellitus) and type 2 diabetes (noninsulin dependent diabetes mellitus) and the latter account for $> 90\%$ of all diabetic cases. It is estimated that more than 170 million people worldwide suffer from diabetes and the number is predicted to double to $> 300$ million by the year 2030 [1]. In type 2 diabetes mellitus, insulin resistance and relative deficiency of insulin secretion are two characteristic features and current clinical therapies mainly focus on increasing plasma insulin level by direct insulin administration and oral agents that promote insulin secretion, improving insulin sensitivity by drugs such as thiazolidinediones (TZDs) and delaying the digestion and absorption of carbohydrate from the gastrointestinal tract by inhibition of $\alpha$-glucosidase [2]. Rosiglitazone (BRL49653), one of the thiazolidinedione anti-hyperglycemic drugs, is identified as synthetic ligand for peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$) which is a member of the nuclear hormone receptor superfamily [3]. Rosiglitazone is used clinically to improve insulin sensitivity and lower blood glucose in diabetic patients [4, 5]. In the present study, rosiglitazone was used for the positive control.

Recently, the search for appropriate antidiabetic agents from traditional herbal medicines has been an important strategy [6–9]. *Picris japonica* Thunb recorded as herbal medicine is traditionally used for the treatment of respiratory system diseases in China [10]. In some regions, it is also used for diet and the treatment of diabetic mellitus. Other data related to *Picris japonica* are very few. It was reported that *Picris japonica* aqueous extract exhibited remarkable hypoglycemic effect in alloxan-induced diabetic rat model [11]. However, KK-AY mice model is one of the useful type 2 diabetic models due to its various characteristics such as hyperglycemia, glucose intolerance, insulin resistance, and increased gluconeogenesis and is widely used for evaluation of antidiabetic agents [12, 13]. So, in the present study, KK-AY diabetic mice model is used to evaluate the antidiabetic effects of *Picris japonica* aqueous extract through measurement of blood glucose, glucose tolerance ability, and plasma insulin level as well as blood lipid to further provide a basis for
the application of *Picris japonica* in the treatment of type 2 diabetes mellitus.

2. Methods

2.1. Preparation of *Picris Japonica* Extract. The whole herbal plants of *Picris japonica* were collected in Fangshan county, Shanxi Province and identified by Jia Yanmei (Fenyang College of Shanxi Medical University). A voucher specimen (2016-07) was deposited in Fenyang College of Shanxi Medical University, China.

The pieces of herbal were mixed with water (1:5, w/v) and extracted at 60°C for 2 h. The extract was filtered and freeze-dried to obtain the freeze-dried powder. Then the powder was suspended in saline to prepare 0.1 g/ml solution and stored at 4°C for use.

2.2. Phytochemical Detection for PJE. The phytochemical evaluation of the PJE was performed by specific procedures for the detection of total phenolic, total flavonoids, and total saponins as described in previous studies [14–16]. Gallic acid, rutin, and ursolic acid were used for analytic standards to construct the calibration curves. All experiments were carried out in triplicate and the results were presented as standard equivalents.

2.3. Animals. Animal experiments were carried out under principles in good laboratory animal care and approved by ethical committee for Laboratory Animals Care and Use of Fenyang College of Shanxi Medical University. KK-A^Y^ mice (7 weeks old) were obtained from Institute of Laboratory Animals, Chinese Academy of Medical Sciences, Beijing, China (SCXK 2005-0013). Before and during the experiments, the mice were housed in cages and maintained in 12 h light/dark cycle at a ambient temperature (22 ± 2°C) and humidity (50 ± 10%). All mice were given a high-fat diet (GB14924.3-2001).

2.4. Experimental Design. After four weeks of high-fat diet feeding, the fasted blood glucose levels of the mice were tested, and the mice who were fasted blood glucose levels ≥ 11.2 mmol/L were determined as type 2 diabetes mellitus.

Then, the mice were divided randomly into four groups (n = 10 for each group). Group 1, diabetic control mice fed with saline; Group 2, diabetic mice fed with 700 mg/kg PJE; Group 3, diabetic mice fed with 350 mg/kg PJE; Group 4, diabetic mice fed with 4 mg/kg Rosiglitazone (GlaxoSmithKline, Tianjing, China). Body weight was measured at 7th and 14th day. After continuous feeding for 14 days, blood samples were collected from tail vein in heparin-containing sample tubes. Then the samples were centrifuged at 4°C (6000 g, 10 min) to collect plasma which was stored at −20°C for use.

2.5. Blood Glucose Level. Blood glucose level was assayed by a commercial glucose kit based on the glucose oxidase method (BioSino Bio-technology and Science Inc., Beijing, China).

2.6. Oral Glucose Tolerance Test (OGTT). KK-A^Y^ mice were treated as described above in Experimental design for 12 days and then were administered orally with glucose solution (2.5 g/kg) and blood samples were collected from tail vein at 0, 30, 60, and 120 min and blood glucose levels of all blood samples were measured by a commercial glucose kit.

2.7. Plasma Insulin Level. After administration for 14 days, blood samples were prepared and plasma insulin level was determined by enzyme linked immunosorbent assay kit (Beijing FuRui Biological Engineering Company, Beijing, China).

2.8. Blood Lipid Level. After administration for 14 days, blood samples were prepared and plasma TC, TG, HDL, and LDL levels were determined by commercial assay kits (BioSino Bio-technology and Science Inc., Beijing, China).

2.9. Statistical Analysis. The results were expressed as mean ± SD and statistical significance was determined by one-way ANOVA followed by Dunnet t-test. p < 0.05 was regarded as significant difference between groups.

3. Results

3.1. Phytochemical Composition of PJE. The main composition of PJE and calibration curves parameters were presented in Table 1.

3.2. Effect of PJE on Body Weight in KK-A^Y^ Mice. As shown in Table 2, there was no obvious increase in mice body weight during the experiment and all mice were at a normal range in body weight, which demonstrated that no obesity occurred in all mice. Meanwhile, the study found that PJE had no effect on the body weight of KK-A^Y^ mice during the 14-day period of treatment compared with diabetic control mice.

3.3. Effect of PJE on Blood Glucose Level in KK-A^Y^ Mice. As shown in Figure 1, the blood glucose levels in mice of different groups were maintained at around 11 mmol/L before administration. The blood glucose level in diabetic control mice increased from 11.1 to 11.7 and 12.6 mmol/L at 7th and 14th day, respectively. Oral administration of PJE for 7 days.
and 14 days caused a significant decrease in blood glucose level in a dose-dependent manner compared with the control diabetic group (\( p < 0.05 \) or \( p < 0.01 \)). Administration of Rosiglitazone also significantly decreased blood glucose level of mice compared with the control diabetic group (\( p < 0.01 \)).

There was no significant difference between the PJE groups and the Rosiglitazone group.

### 3.4. Effect of PJE on Oral Glucose Tolerance Test in KK-A\(^y\) Mice.

As shown in Figure 2, oral administration of PJE for 12 days appeared to obviously improve the glucose tolerance of KK-A\(^y\) mice. The control diabetic mice showed a sharp increase from 12.5 ± 1.89 mmol/L to 24.4 ± 2.47 mmol/L in blood glucose level at 30 min after oral administration of 2.5 g/kg glucose and maintained high level of blood glucose for over an additional 30 min. All PJE-treated and Rosiglitazone-treated mice also showed sharp increases in blood glucose level at 30 and 60 min after oral administration of 2.5 g/kg glucose. However, compared with the control diabetic group, PJE- and Rosiglitazone-treated mice showed significant lower level in blood glucose (\( p < 0.01 \)).

### 3.5. Effect of PJE on Blood Insulin Level in KK-A\(^y\) Mice.

As shown in Table 3, oral administration of PJE (700 mg/kg) and Rosiglitazone-treated mice compared with the diabetic control (\( p < 0.01 \)), which illustrated that PJE can relieve the insulin tolerance in the KK-Ay mice.

### 3.6. Effect of PJE on Blood Lipid Level in KK-A\(^y\) Mice.

As shown in Table 3, oral administration of PJE (700 mg/kg)
and Rosiglitazone for 14 days showed different effects on total cholesterol, triglyceride, high density lipoprotein cholesterol, and low density lipoprotein cholesterol in KK-Ay mice fed with a high-fat diet. Compared with the control diabetic group, the serum total cholesterol, triglyceride, and low density lipoprotein cholesterol were reduced by PJE (700 mg/kg) and Rosiglitazone (p < 0.05), and the serum high density lipoprotein cholesterol was significantly increased only by Rosiglitazone (p < 0.01). PJE (350 mg/kg) exhibited no effect on blood lipid.

4. Discussion

The purpose of the present study was to evaluate the hypoglycemic activity of Picris japonica aqueous extract in KK-Ay diabetic mice. Hyperglycemia, insulin resistance, and dysfunction of insulin secretion are major characteristic features of type 2 diabetes mellitus. In a previous report, the alloxan-induced diabetic mice model was used to evaluate the antidiabetic effect of Picris japonica aqueous extract. This chemically induced diabetic model was based on the unique capability of alloxan to selectively destroy the pancreatic beta cells, which was pathologically similar to type 1 diabetes mellitus [17]. The model of KK-Ay mice was a spontaneously diabetic model, which was established by transferring the yellow obese gene (A') into KK mice. This diabetic model was a relevant model of human type 2 diabetes mellitus due to its related changes in systemic organs and used worldwide for the assessment of pharmacological effects of new antidiabetes agents [18]. Therefore, KK-Ay mice were used for assessment of the antidiabetic activity of Picris japonica in the present study to further provide evidence for the application of Picris japonica Thunb in type 2 diabetes mellitus.

Hyperglycemia, a principal symptom in type 2 diabetic mellitus, is widely perceived as contributing to the diabetic retinopathy and other diabetic complications. Hyperglycemia activates polyol pathway which is a two-step metabolic pathway where glucose is reduced to sorbitol first and then sorbitol is converted into fructose. Under hyperglycemic conditions, sorbitol accumulates in tissues like retina, kidney, peripheral nerves, and blood vessels where it causes osmotic damage to the tissues [19–21]. Meanwhile, hyperglycemia leads to accumulation of advanced glycation end products (AGEs) which are nonenzymatically glycated and oxidized proteins and lipids. AGEs activate protein kinase C (PKC) and poly (ADP-ribose) polymerase both of which initiate inflammation in tissues [22]. Stratton et al. also proposed that hyperglycaemia was strongly associated with the risk of diabetic complications in patients with type 2 diabetes based on a clinical study of 4585 patients [23].

Type 2 diabetes is noninsulin dependent and occurs as a result of insulin resistance and deficiency in insulin secretion. The action of insulin is to promote carbohydrate uptake and conversion to lipids. Insulin resistance refers to the condition where the insulin is not very effective in the conversion from glucose to lipid, which gives rise to high blood glucose levels. In the present study, Picris japonica aqueous extract significantly reduced blood glucose level, increased blood insulin level, and regulated blood lipid level compared with the control diabetic group, which indicated that Picris japonica maybe a potential agent for the intervention of diabetic complications.

5. Conclusion

The findings demonstrate that Picris japonica has a remarkable hypoglycemic effect in diabetic KK-Ay mice suggesting that Picris japonica may be beneficial in the treatment of type 2 diabetes mellitus.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
The present study was supported financially by College students' innovative entrepreneurial training plan of Shanxi Province, China (2017532).

References
[1] P. Zimmet, K. G. M. M. Alberti, and J. Shaw, "Global and societal implications of the diabetes epidemic," Nature, vol. 414, no. 6865, pp. 782–787, 2001.
[2] E. J. Verspohl, "Novel pharmacological approaches to the treatment of type 2 diabetes," Pharmacological Reviews, vol. 64, no. 2, pp. 188–237, 2012.
[3] T. M. Willson and W. Wahli, "Peroxisom proliferator-activated receptor agonists," Curr Opin Chem Biol, vol. 1, pp. 235–241, 1997.
[4] A. B. Mayerson, R. S. Hundal, S. Dufour et al., "The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes," Diabetes, vol. 51, no. 3, pp. 797–802, 2002.
[5] P. Raskin, E. B. Rappaport, S. T. Cole, Y. Yan, R. Patwardhan, and M. I. Freed, "Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes," Diabetologia, vol. 43, no. 3, pp. 278–284, 2000.
[6] K. Rathore, V. K. Singh, P. Jain, S. P. Rao, Z. Ahmed, and V. D. Singh, "In-vitro and in-vivo antidiaplogenic, hypolipidemic and antidiabetic activity of Diospyros melanoxylon (Roxb)," Journal of Ethnopharmacology, vol. 155, no. 2, pp. 1173–1176, 2014.
[7] S.-S. Huang, Y.-H. Yan, C.-H. Ko, K.-M. Chen, S.-C. Lee, and C.-T. Liu, "A comparison of food-grade folium mori (Sàng Yè) extract and 1-deoxynojirimycin for glycemic control and renal function in streptozotocin-induced diabetic rats," Journal of Traditional and Complementary Medicine, vol. 4, no. 3, pp. 162–170, 2014.
[8] D. S. Sales, F. Carmona, B. C. De Azevedo et al., "Eugenia punicifolia (Kunth) DC. as an adjuvant treatment for type-2 diabetes mellitus: A non-controlled, pilot study," Phytotherapy Research, vol. 28, no. 12, pp. 1816–1821, 2014.
[9] N. A. Shah and M. R. Khan, "Antidiabetic effect of Side cordata in alloxan induced diabetic rats," BioMed Research International, vol. 2014, Article ID 671294, 15 pages, 2014.
[10] C. S. Qian and H. Y. Chen, Flora of China, Science Press (Beijing), 2004.
[11] Z. Y. Zhang, R. Ge, E. L. Liu, and J. P. Gao, "Study on hypoglycemic effect by Picris iaponica," Chinese J Exp Tradit Med Formulae, vol. 18, pp. 215–218, 2012.
[12] H. Ikeda, "KK mouse," Diabetes Research and Clinical Practice, vol. 24, pp. S313–S316, 1994.
[13] R. Zhang, Y. Yao, Y. Wang, and G. Ren, "Antidiabetic activity of isoquercetin in diabetic KK-Ay mice," Nutrition & Metabolism, vol. 8, article 85, 2011.
[14] SH. Liu, XJ. Meng, T. Niu, and JQ. Wang, "Determination of total polyphenol in grape seeds," Chin J Trad Chin Med Pharm, vol. 22, pp. 715-716.
[15] Y. J. Guo, L. Fan, X. Q. Wang, and L. Z. Zhang, "Discussion about NaNO2-Al(NO3)3-NaOH Colorimetry for Determination of Total Flavonoids," Chin J Pharm Anal, vol. 22, pp. 97–99, 2002.
[16] L. Yue, D. N. Zhu, Y. Q. Yan, and B. Y. Yan, "Determination of total saponins in Shengmai Powders Preparation," Trad Chin Med Pat Pres, vol. 11, pp. 897–900, 2004.
[17] R. H. Bell Jr. and R. J. Hye, "Animal models of diabetes mellitus: physiology and pathology," Journal of Surgical Research, vol. 35, no. 5, pp. 433–460, 1983.
[18] T. Moroki, Y. Yoshikawa, K. Yoshizawa, A. Tsubura, and H. Yasui, "Morphological characterization of systemic changes in KK-Ay mice as an animal model of type 2 diabetes," In Vivo, vol. 27, no. 4, pp. 465–472, 2013.
[19] S. Z. Safi, R. Qvist, S. Kumar, K. Batumalai, and I. S. B. Ismail, "Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets," BioMed Research International, vol. 2014, Article ID 801269, 18 pages, 2014.
[20] K. H. Gabbay, "The sorbitol pathway and the complications of diabetes," The New England Journal of Medicine, vol. 288, no. 16, pp. 831–836, 1973.
[21] Z. Dagher, Y. S. Park, V. Asnaghi, T. Hoehn, C. Gerhardinger, and M. Lorenzi, "Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy," Diabetes, vol. 53, no. 9, pp. 2404–2411, 2004.
[22] M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, no. 6865, pp. 813–820, 2001.
[23] I. M. Stratton, A. I. Adler, H. A. W. Neil et al., "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study," British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000.